Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal in Arkansas?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Yes, with a stricter first-visit rule than most states. An Arkansas resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from an Arkansas-licensed provider, including by telemedicine under the Arkansas Telemedicine Act (Ark. Code 17-80-401 through 17-80-407), but a new telemedicine patient relationship cannot rest on an internet questionnaire, email, patient-generated medical history, text message, or fax, alone or in any combination; it needs an in-person exam, an existing relationship, referral, or coverage arrangement, or an evaluation by an Arkansas-licensed provider who has access to a personal health record maintained by a healthcare professional and uses appropriate technology, which for non-controlled drugs can include the telephone. Compounded peptides are available only when eligible under federal 503A rules and dispensed by an Arkansas-licensed pharmacy; an out-of-state pharmacy shipping into Arkansas must hold an Arkansas pharmacy license and keep an Arkansas-licensed pharmacist on staff as pharmacist in charge.

Regulatory: Telehealth allowedRegulatory: Async not allowedRegulatory: Compounded GLP-1 limitedVerified: Verified Oct 28, 2026
Compounding rules
Follows the federal 503A framework
Telehealth prescribing
Allowed, asynchronous not allowed; a questionnaire alone is not enough
Compounded GLP-1
Limited

Can a Arkansas resident get peptides by telehealth?

The Arkansas Telemedicine Act (Ark. Code 17-80-401 through 17-80-407, amended by Acts 767, 829, and 1112 of 2021) defines telemedicine to include store-and-forward technology and remote patient monitoring, but defines store-and-forward as the asynchronous transmission of a patient's medical information from one healthcare professional to another, not from a patient to a provider. Section 17-80-403 bars a distant-site professional from using telemedicine with an Arkansas patient unless a professional relationship exists. Section 17-80-402(4) lists how that relationship can exist: a prior in-person exam, personal knowledge through an ongoing relationship, consultation with or referral from a professional who has a relationship with the patient, an on-call or cross-coverage arrangement, circumstances defined by board rule, or, since 2021, an Arkansas-licensed professional who has access to a personal health record maintained by a healthcare professional and uses any technology the professional deems appropriate, including the telephone, to diagnose, treat, and if clinically appropriate prescribe a noncontrolled drug. A health record may be created with the use of telemedicine if the in-person standard of care is met, and the Arkansas State Medical Board's rule (17 CAR 140-202(b)(8)) repeats this. Section 17-80-403(c) says a professional relationship does not include one established only by an internet questionnaire, email, patient-generated medical history, text messaging, fax, or any combination of them, and the Board's telemedicine rule (17 CAR 140-3201) adds that a patient completing a medical history online and forwarding it is not sufficient and does not qualify as store-and-forward. The treating provider must be licensed in Arkansas. This record classifies asynchronous prescribing as not allowed because no Arkansas provision expressly lets a new patient relationship be formed by asynchronous means, and the statute and Board rule together exclude the patient-to-provider asynchronous channels (questionnaire, email, text, patient-written history) alone or in combination. A telephone or video evaluation that builds a proper health record can support a first non-controlled prescription. [2] [3] [8] [9]

How does the Arkansas pharmacy board treat compounding?

Compounding regulator for Arkansas
BoardArkansas State Board of Pharmacy
Eligible substancesFollows the federal 503A framework

The Arkansas State Board of Pharmacy regulates compounding under the Pharmacy Practice Act (Ark. Code Title 17, Chapter 92) and its compounding rule, now codified in the Code of Arkansas Rules as 17 CAR 160-2201 (Standards for compounding and dispensing compounded products, as amended effective June 29, 2026). That rule requires compounding pharmacies to comply with section 503A of the federal Food, Drug, and Cosmetic Act and the USP chapters on compounding numbered below 1000, generally prohibits compounding a drug that is commercially available or essentially a copy of an FDA approved product unless the prescriber documents a patient-specific medical need or the product is documented as unavailable, and requires a pharmacist in charge who oversees sterile compounding to keep written sterile procedures and certify Board-approved sterile training for pharmacists and technicians. Arkansas has no state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Arkansas is unusual in its nonresident rule: Ark. Code 17-92-401 requires any pharmacy outside the state that routinely ships dispensed legend drugs into Arkansas to hold an Arkansas pharmacy license, follow Arkansas law for the Arkansas part of its operation, keep an Arkansas-licensed pharmacist on staff as pharmacist in charge, and register an Arkansas agent for service of process. [1] [5] [6] [7] [12]

Can you get compounded GLP-1s in Arkansas?

Regulatory: Compounded GLP-1 limited

Compounded semaglutide and tirzepatide are limited to documented patient-specific needs after the FDA shortage allowances ended in 2025, and Arkansas's own compounding regulation separately bars routine copies of commercially available drugs. Because Arkansas law does not let an online questionnaire alone establish the patient relationship, Arkansas patients should expect an in-person exam, a referral or existing relationship, or an evaluation by an Arkansas-licensed provider who has access to a personal health record maintained by a healthcare professional (by telephone, video, or other appropriate technology) before a first GLP-1 prescription, and should confirm the dispensing pharmacy holds an Arkansas license with an Arkansas-licensed pharmacist in charge. [2] [3] [5] [7] [15]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in Arkansas?

Access options

We may earn a commission from these links.

Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.

Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.

Find a provider in Arkansas

What you'll actually find in Arkansas, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [19] [20] [21]

No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [22]

What Arkansas has done

PeptideAgent has not found a board or legislative action on peptides in Arkansas.

Other states have acted:

  • On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [24] Mississippi law
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [25] [26] Louisiana law

Checking the prescriber

Telehealth prescribing of non-controlled peptides is permitted in Arkansas. Expect a live video or phone visit; prescribing without one is not permitted. State law says an online questionnaire alone is not enough. [2] [3] [8] [9] The telehealth rule in full.

Checking the pharmacy

Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the Arkansas State Board of Pharmacy; its license search: FDA BeSafeRx: state board of pharmacy license lookups. [23]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [22]

They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [13] [27] [28]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [23] [29] [30]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [21] [30] [31]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [22] [32] [33] [34] [35] [36]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [22]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [23]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [21]
  • Pharmacy: Is this made for me on a prescription written in my name? [31]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [21] [30]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [21]

What is offered for a specific peptide, and what FDA found, is on each peptide page.

Is it legal to buy research peptides in Arkansas?

Only Arkansas-licensed pharmacies may dispense prescription drugs to Arkansas patients, including out-of-state pharmacies licensed under Ark. Code 17-92-401. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling, are not dispensed by a pharmacist, and carry no Arkansas licensing protections. The Arkansas Food, Drug, and Cosmetic Act (Ark. Code 20-56-201 and following) has no separate new-drug approval section, so the unapproved-drug prohibition comes from federal law; the state act does prohibit selling a misbranded drug (Ark. Code 20-56-215) and treats a drug as misbranded unless its labeling bears adequate directions for use and adequate warnings (Ark. Code 20-56-211). [5] [10] [11] [16]

Peptide-specific notes for Arkansas

Peptide-specific notes for Arkansas
PeptideNote
SemaglutideAvailable branded by prescription. A first prescription by telemedicine requires a professional relationship under Ark. Code 17-80-402 and 17-80-403, such as an in-person exam, an existing relationship or referral, or an evaluation by an Arkansas-licensed provider with access to a personal health record maintained by a healthcare professional (telephone allowed for non-controlled drugs). A questionnaire, email, text, fax, or patient-written history, alone or combined, does not qualify. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [2] [3] [15]
TirzepatideAvailable branded by prescription. Compounded tirzepatide is limited to documented patient-specific needs since the 503A grace period ended February 18, 2025, and an out-of-state pharmacy shipping it to Arkansas must hold an Arkansas license with an Arkansas-licensed pharmacist in charge. [5] [15]

Compare: Wegovy vs Zepbound.

Frequently asked questions

Can I get a GLP-1 prescription in Arkansas from an online questionnaire alone?

No. The Arkansas Telemedicine Act requires a professional relationship before telemedicine care and says a relationship established only by an internet questionnaire, email, patient-generated medical history, text message, or fax, or any combination of them, does not count. For a new patient the relationship can come from an in-person exam, a referral from a professional who knows you, or an evaluation by an Arkansas-licensed provider who has access to your personal health record maintained by a healthcare professional and uses appropriate technology, which for non-controlled drugs such as GLP-1s can include a telephone call. [2] [3] [8] [9]

Does a telehealth prescriber need an Arkansas license?

Yes. Ark. Code 17-80-404 and the Arkansas State Medical Board's telemedicine rule (17 CAR 140-3201) require a professional treating a patient located in Arkansas through telemedicine to be licensed in Arkansas. Check the prescriber on the Arkansas State Medical Board license lookup before paying. [4] [9]

What does an out-of-state pharmacy need to ship compounded peptides to Arkansas?

An Arkansas pharmacy license. Ark. Code 17-92-401 also requires the pharmacy to keep an Arkansas-licensed pharmacist on staff as pharmacist in charge for its Arkansas business and to register an Arkansas agent for service of process. If the pharmacy is not in the Board of Pharmacy license lookup, the shipment is not lawful. [1] [5] [6]

Is compounded semaglutide or tirzepatide still available in Arkansas?

Only in limited, patient-specific cases. The federal shortage allowances ended in 2025, and Arkansas's compounding regulation generally bars compounding copies of commercially available drugs unless the prescriber documents a patient-specific medical need. [7] [15]

Can an Arkansas pharmacy compound BPC-157?

Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: Arkansas has no state bulks list, so peptide eligibility follows the federal 503A framework, and Board rules require compounding pharmacies to comply with section 503A. [7] [13] [14] [17] [18]

From the blog

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.

  1. [1]Arkansas State Board of Pharmacy
  2. [2]Arkansas Code 17-80-402, Telemedicine Act definitions (professional relationship, store-and-forward)
  3. [3]Arkansas Code 17-80-403, Establishment of professional relationship
  4. [4]Arkansas Code 17-80-404, Appropriate use of telemedicine
  5. [5]Arkansas Code 17-92-401, Applicability to out-of-state operations (pharmacies)
  6. [6]Code of Arkansas Rules 17 CAR 160-1401, Out-of-state pharmacy regulation
  7. [7]Code of Arkansas Rules 17 CAR 160-2201, Standards for compounding and dispensing compounded products (Ark. R. 2026-88, effective June 29, 2026), accessed 2026-09-22
  8. [8]Code of Arkansas Rules 17 CAR 140-202, Arkansas State Medical Board: minimum standards for establishing patient/provider relationships (paragraph (b)(8)), accessed 2026-09-22
  9. [9]Code of Arkansas Rules 17 CAR 140-3201, Arkansas State Medical Board: requirements for services provided using telemedicine, accessed 2026-09-22
  10. [10]Arkansas Code 20-56-211, Misbranded drug or device (Food, Drug, and Cosmetic Act), accessed 2026-09-22

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Are peptides legal in Arkansas?. https://peptideagent.ai/legal/arkansas
HTML link
<a href="https://peptideagent.ai/legal/arkansas">Are peptides legal in Arkansas?</a>, PeptideAgent, updated October 28, 2026.